Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076342 · ClinicalTrials.gov registry record · Phase 4
The Role of mGluR5 in CBT-I
A Phase 4 study of Major Depressive Disorder (MDD), sponsored by Stony Brook University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT07076342: Recruiting Phase 4 study of Major Depressive Disorder (MDD), sponsored by Stony Brook University.
NCT07076342 is a Phase 4 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 42 participants, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076342, a Phase 4 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
Primary Outcome
Polysomnography: Prior to and following CBT-I, participants will spend one or two nights in the facility's Sleep Lab in order to assess sleep latency (i.e., quantity of sleep). While the participant sleeps, polysomnography, including EEG will be collected. This will be used to quantify sleep latency.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy for Insomnia
- DRUG PET Scan with [11C]ABP688
Study Locations (1)
New York
- Stony Brook University: Dept of Psychiatry - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 4 |
What NCT07076342 shows while recruiting
NCT07076342 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Behavioral Therapy for Insomnia is the first listed.
NCT07076342 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07076342 about?
NCT07076342 is a clinical study titled "The Role of mGluR5 in CBT-I". This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
What is the current status of trial NCT07076342?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2025-08-01. Estimated completion is 2030-03-31.
What conditions does trial NCT07076342 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT07076342?
The interventions under investigation include: Cognitive Behavioral Therapy for Insomnia (BEHAVIORAL), PET Scan with [11C]ABP688 (DRUG).
Who is sponsoring clinical trial NCT07076342?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076342 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07076342's enrollment target sits among peer trials
42 16th of 22 higher than 7 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
RECRUITING · Phase 4
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
Neurofeedback to Treat Depression - 2
RECRUITING · NA
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI